U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Chash the Lapsive KT to add at 17 tot of 1000; the poles				to are required to respect to a solicotion of information a needs it serial to a valid crivib serial from			
Substitute for form 1449A/PTO				Complete if Known			
				Application Number	10/821,930		
INFO	RMATION	DIS	CLOSURE	Filing Date	April 12, 2004		
STATEMENT BY APPLICANT				First Named Inventor	Dario NERI		
				Art Unit	1645		
(Use as many sheets as necessary)			necessary)	Examiner Name	Virginia Allen PORTNER		
Sheet	1	of	1	Attorney Docket Number	FLLIS-0002-P02-C01		

	U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
		Number - Kind Code <sup>2</sup> ( <i>if known</i> )			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code <sup>3</sup> - Number <sup>4</sup> – Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY			T <sup>6</sup>
		WO 1995/32001	11-30-1995	Giovanni Neri		Х

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	, I will have the transfer that the transfer that the transfer to the transfer transfer to the transfer transfer to the transfer transfer transfer to the transfer tr			
		CHEN, et al., "Adhesion Mediated by Fibronectin's Alternatively Spliced ED <sub>b</sub> (EIIIB) and Its Neighboring Tyoe III Repeats," Experimental Cell Research 223, 9-19 (1996), Article No. 0053.			
		KIM, et al., "Regulation of Angiogenesis in Vivo by Ligation of Integrin α5β1 with the Central Cell-Binding Domain of Fibronectin," American Journal of Pathology, Bol. 156, No. 4, April 2000, pages 1345-1362.			
		GLOCKSHUBER, R., et al., "A Comparison of Strategies to Stabilize Immunoglobulin F <sub>v</sub> -Fragments," Biochemistry 1990, 29, 1362-1367.			

Date

Considered

Examiner

Signature

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.